Biogen (NASDAQ:BIIB) Q4 CY2025: Revenue Misses, EPS Beats Estimates Despite 7.1% Drop

Biogen (NASDAQ:BIIB) topped earnings expectations in Q4 CY2025, reporting adjusted EPS of $1.99, 22.1% above consensus, but revenue fell 7.1% year on year to $2.28B. Sales momentum weakened over five years, down 6% annually, with operating margins contracting 8.6 pp and EPS declining 14.2% annually. Analysts project revenue to decline 6.6% and full-year EPS to $15.29, down 5.6% from prior-year guidance. The stock closed flat at $185.89.